Wellington Management Group LLP Purchases 36,267 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Wellington Management Group LLP grew its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 107.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 70,170 shares of the company’s stock after buying an additional 36,267 shares during the quarter. Wellington Management Group LLP owned 0.15% of Enliven Therapeutics worth $1,792,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Bank of New York Mellon Corp grew its position in Enliven Therapeutics by 49.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after acquiring an additional 37,632 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Enliven Therapeutics by 29.9% in the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after purchasing an additional 11,420 shares during the last quarter. Quest Partners LLC grew its holdings in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the last quarter. American Century Companies Inc. increased its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after buying an additional 8,540 shares during the period. Finally, Nicholas Investment Partners LP bought a new stake in Enliven Therapeutics during the 2nd quarter valued at about $1,310,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 7,522 shares of the stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $206,930.22. Following the completion of the sale, the insider now owns 1,069,887 shares of the company’s stock, valued at $29,432,591.37. This represents a 0.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Benjamin Hohl sold 5,250 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50. The disclosure for this sale can be found here. In the last three months, insiders sold 129,195 shares of company stock valued at $3,581,772. Corporate insiders own 29.20% of the company’s stock.

Enliven Therapeutics Stock Down 7.7 %

Shares of NASDAQ:ELVN opened at $22.50 on Thursday. The firm has a 50 day moving average of $26.29 and a 200 day moving average of $24.19. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -11.84 and a beta of 1.02. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03.

Wall Street Analyst Weigh In

ELVN has been the topic of a number of research reports. Robert W. Baird raised their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Finally, BTIG Research initiated coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.